Autor(es)
Afiliação
Resumo em Inglês
Adverse effects (AE) to TB treatment
cause morbidity, mortality and treatment interruption.
The aim of these clinical standards is to encourage best
practise for the diagnosis and management of AE.
METHODS : 65/81 invited experts participated in a
Delphi process using a 5-point Likert scale to score
draft standards.
Editor
The Union
Referência
SINGH, K. P. et al. Clinical standards for the management of adverse effects during treatment for TB. Int. J. Tuberc Ling Dis., v. 27, n.7, p. 506-519, Feb. 2023.
DOI
10.5588/ijtld.23.0078
ISSN
18157920
Notas
AUTORES:
FIOCRUZ. IOC - = A. C. C. Carvalho
K. P. Singh,1,2 A. C. C. Carvalho,3 R. Centis,4
L. D’Ambrosio,5 G. B. Migliori,4 S. G. Mpagama,6,7
B. C. Nguyen,8 R. E. Aarnoutse,9 A. Aleksa,10
R. van Altena,11 P. K. Bhavani,12 M. S. Bolhuis,13 S. Borisov,14 N. van’t Boveneind-Vrubleuskaya,13,15
J. Bruchfeld,16,17 J. A. Caminero,18,19 I. Carvalho,20
J. G. Cho,21,22,23 L. Davies Forsman,16,17,24
M. Dedicoat,25 K. Dheda,26,27,28 K. Dooley,29
J. Furin,30 J. M. Garc´ıa-Garc´ıa,31
A. Garcia-Prats,32,33 A. C. Hesseling,32
S. K. Heysell,34 Y. Hu,35 H. Y. Kim,21,22,24
S. Manga,36 B. J. Marais,21,37 I. Margineanu,13 AG.
M¨artson,38 M. Munoz Torrico,39
H. M. Nataprawira,40 E. Nunes,41,42
C. W. M. Ong,43,4,45 R. Otto-Knapp,46
D. J. Palmero,47 C. A. Peloquin,48 A. Rendon,49
D. Rossato Silva,50 R. Ruslami,51,52
A. M. I. Saktiawati,53,54 P. Santoso,55 H. S. Schaaf,32
B. Seaworth,56 U. S. H. Simonsson,57 R. Singla,58
A. Skrahina,59 I. Solovic,60 S. Srivastava,56,61,62
S. L. Stocker,24,63 M. G. G. Sturkenboom,13
E. M. Svensson,9,64 M. Tadolini,65,66
T. A. Thomas,34 S. Tiberi,67 J. Trubiano,1,68
Z. F. Udwadia,69 A. R. Verhage,70 D. H. Vu,71
O. W. Akkerman,72,73 J. W. C. Alffenaar,21,22 24
J. T. Denholm1,2,74
KPS, ACCC, RC, LDA, GBH, SGM, BCN, OWA,
JWCA and JTD comprised the core writing team.
OWA, JWCA and JTD were senior authors.
1Department of Infectious diseases, University of
Melbourne, at the Peter Doherty Institute for
Infection and Immunity, Melbourne, VIC, 2Victorian
Infectious Disease Unit, Royal Melbourne Hospital,
VIC, Australia; 3Laboratório de Inovações em
Terapias, Ensino e Bioprodutos (LITEB), Instituto
Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de
Janeiro, RJ, Brazil; 4Servizio di Epidemiologia Clinica
delle Malattie Respiratorie, Istituti Clinici Scientifici
Maugeri Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS), Tradate, Italy; 5Public Health
Consulting Group, Lugano, Switzerland;
6Kilimanjaro Christian Medical University College,
Moshi, 7Kibong’oto Infectious Diseases Hospital,
Sanya Juu, Siha, Kilimanjaro, United Republic of
Tanzania; 8Woolcock Institute of Medical Research,
Viet Nam and University of Sydney, NSW, Australia;
9Department of Pharmacy, Research Institute for
Medical Innovation, Radboud University Medical
Center, Nijmegen, The Netherlands; 10Grodno State
Medical University, Grodno, Belarus; 11Asian Harm
Reduction Network (AHRN) and Medical Action
Myanmar (MAM), Yangon, Myanmar; 12Indian
Council of Medical Research-National Institute for
Research in Tuberculosis; 13Department of Clinical
Pharmacy and Pharmacology, University Medical
Center Groningen, University of Groningen,
Groningen, the Netherlands; 14Moscow Research
and Clinical Center for Tuberculosis Control,
Moscow, Russia; 15Department of Public Health TB
Control, Metropolitan Public Health Services, The
Hague, The Netherlands; 16Departement of Medicine
Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden; 17Departement of
Infectious Diseases, Karolinska University Hospital,
Stockholm, Sweden; 18Department of Pneumology.
University General Hospital of Gran Canaria ‘‘Dr
Negrin’’, Las Palmas, Spain; 19ALOSA (Active
Learning over Sanitary Aspects) TB Academy, Spain;
20Paediatric Department, Vila Nova de Gaia Hospital
Centre, Vila Nova de Gaia Outpatient Tuberculosis
Centre, Vila Nova de Gaia, Portugal; 21Sydney
Infecious Diseases Institute (Sydney ID), The
University of Sydney, Sydney, NSW, Australia;
22Westmead Hospital, Sydney, NSW, Australia;
23Parramatta Chest Clinic, Parramatta, NSW,
Australia; 24School of Pharmacy, Faculty of Medicine
and Health, The University of Sydney, Sydney, NSW,
Australia; 25Department of Infectious Diseases,
Heartlands Hospital, University Hospitals
Birmingham NHS Foundation Trust, Birmingham,
UK; 26Centre for Lung Infection and Immunity Unit,
Department of Medicine, Division of Pulmonology
and UCT Lung Institute, University of Cape Town,
Cape Town, 27South African Medical Research
Council Centre for the Study of Antimicrobial
Resistance, University of Cape Town, Cape Town,
South Africa; 28Faculty of Infectious and Tropical
Diseases, London School of Hygiene & Tropical
Medicine, London, UK; 29Division of Infectious
Diseases, Department of Medicine, Vanderbilt
University Medical Center, Nashville, TN,
30Department of Global Health and Social Medicine,
Harvard Medical School, Boston, MA, USA;
31Tuberculosis Research Programme, SEPAR
(Sociedad Espanõla de Neumolog´ıa y Cirug´ıa
Tora´ cica), Barcelona, Spain; 32Desmond Tutu TB
Centre, Department of Paediatrics and Child Health,
Stellenbosch University, Tygerberg, South Africa;
33Department of Pediatrics, University of Wisconsin,
Madison, WI, USA; 34Division of Infectious Diseases
and International Health, University of Virginia,
Charlottesville, VA, USA; 35Department of
Epidemiology, School of Public Health and Key
Laboratory of Public Health Safety, Fudan University,
Shanghai, China; 36Tuberculosis Department Latin
American Society of Thoracic Diseases, Lima, Peru;
37Department of Infectious Diseases and
Microbiology, The Children’s Hospital at Westmead,
Westmead, NSW, Australia; 38Centre of Excellence in
Infectious Diseases Research, Antimicrobial
Pharmacodynamics and Therapeutics Group,
Department of Pharmacology and Therapeutics,
University of Liverpool, Liverpool, UK; 39Cl´ınica de
Tuberculosis, Instituto Nacional de Enfermedades
Respiratorias, M´exico City, Mexico; 40Division of
Paediatric Respirology, Department of Child Health,
Faculty of Medicine, Universitas Padjadjaran, Hasan
Sadikin Hospital, Bandung, Indonesia; 41Department
of Pulmonology of Central Hospital of Maputo,
Maputo, 42Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique;
43Infectious Disease Translational Research
Programme, Department of Medicine, Yong Loo Lin
School of Medicine, National University of
Singapore, Singapore, 44National University of
Singapore Institute for Health Innovation &
Technology (iHealthtech), Singapore, 45Division of
Infectious Diseases, Department of Medicine,
National University Hospital, Singapore; 46German
Central Committee Against Tuberculosis (DZK),
Berlin, Germany; 47Hospital Muniz and Instituto
Vaccarezza, Buenos Aires, Argentina; 48Infectious
Disease Pharmacokinetics Laboratory, College of
Pharmacy and Emerging Pathogens Institute,
University of Florida, Gainesville, FL, USA;
49Universidad Autonoma de Nuevo Leon, Facultad
de Medicina, Neumolog´ıa, CIPTIR, Monterrey,
Mexico; 50Faculdade de Medicina, Universidade
Federal do Rio Grande do Sul, Porto Alegre, RS,
Brazil; 51TB/HIV Research Centre, Faculty of
Medicine, Universitas Padjadjaran, Bandung,
Indonesia; 52Department of Biomedical Sciences,
Division of Pharmacology and Therapy, Faculty of
Medicine, Universitas Padjadjaran, Bandung,
Indonesia; 53Department of Internal Medicine,
Faculty of Medicine, Public Health, and Nursing,
Universitas Gadjah Mada, Yogyakarta, Indonesia;
54Centre for Tropical Medicine, Faculty of Medicine,
Public Health and Nursing, Universitas Gadjah
Mada, Yogyakarta, Indonesia; 55Division of
Respirology and Critical Care, Department of
Internal Medicine, Faculty of Medicine, Universitas
Padjadjaran/Hasan Sadikin General Hospital,
Bandung, Indonesia; 56 University of Texas Health
Science Center at Tyler, Tyler, TX, USA;
57Department of Pharmaceutical Biosciences,
Uppsala University, Uppsala, Sweden; 58Department
of TB & Respiratory Diseases, National Institute of
TB & Respiratory Diseases, New Delhi, India;
59Republican Research and Practical Centre for
Pulmonology and Tuberculosis, Minsk, Belarus;
60National Institute of Tuberculosis, Lung Diseases
and Thoracic Surgery, Faculty of Health, Catholic
University, Ruˇzomberok, Vyˇsn´e Ha´gy, Slovakia; 61
Department of Medicine, The University of Texas at
Tyler School ofMedicine, TX, USA; 62Department of
Pharmacy Practice, Texas Tech University Health
Science Center, Dallas, TX, USA; 63Department of
Clinical Pharmacology and Toxicology, St Vincent’s
Hospital, Sydney, NSW, Australia; 64Department of
Pharmacy, Uppsala University, Uppsala, Sweden;
65Infectious Diseases Unit, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Policlinico di
Sant’Orsola, Bologna, Italy; 66Department of
Medical and Surgical Sciences, Alma Mater
Studiorum University of Bologna, Bologna, Italy;
67Blizard Institute, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London, London, UK; 68Department of Infectious
Diseases, Austin Hospital, Melbourne, VIC,
Australia; 69P. D. Hinduja National Hospital and
Medical Research Centre, Mumbai, India;
70Department of Paediatrics, University Medical
Center Groningen, University of Groningen,
Groningen, the Netherlands; 72Department of
Pulmonary Diseases and Tuberculosis, Groningen,
and 73Tuberculosis Center Beatrixoord, University
Medical Center Groningen, University of Groningen,
Haren, the Netherlands; 74Victorian Tuberculosis
Program, Melbourne Health, VIC, Australia.
--------
KPS, ACCC, RC, LDA, GBH, SGM, BCN, OWA,
JWCA and JTD comprised the core writing team.
OWA, JWCA and JTD were senior authors.
1Department of Infectious diseases, University of
Melbourne, at the Peter Doherty Institute for
Infection and Immunity, Melbourne, VIC, 2Victorian
Infectious Disease Unit, Royal Melbourne Hospital,
VIC, Australia; 3Laborat ´ orio de Inova¸c ˜ oes em
Terapias, Ensino e Bioprodutos (LITEB), Instituto
Oswaldo Cruz, Funda¸ca˜o Oswaldo Cruz, Rio de
Janeiro, RJ, Brazil; 4Servizio di Epidemiologia Clinica
delle Malattie Respiratorie, Istituti Clinici Scientifici
Maugeri Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS), Tradate, Italy; 5Public Health
Consulting Group, Lugano, Switzerland;
6Kilimanjaro Christian Medical University College,
Moshi, 7Kibong’oto Infectious Diseases Hospital,
Sanya Juu, Siha, Kilimanjaro, United Republic of
Tanzania; 8Woolcock Institute of Medical Research,
Viet Nam and University of Sydney, NSW, Australia;
9Department of Pharmacy, Research Institute for
Medical Innovation, Radboud University Medical
Center, Nijmegen, The Netherlands; 10Grodno State
Medical University, Grodno, Belarus; 11Asian Harm
Reduction Network (AHRN) and Medical Action
Myanmar (MAM), Yangon, Myanmar; 12Indian
Council of Medical Research-National Institute for
Research in Tuberculosis; 13Department of Clinical
Pharmacy and Pharmacology, University Medical
Center Groningen, University of Groningen,
Groningen, the Netherlands; 14Moscow Research
and Clinical Center for Tuberculosis Control,
Moscow, Russia; 15Department of Public Health TB
Control, Metropolitan Public Health Services, The
Hague, The Netherlands; 16Departement of Medicine
Solna, Division of Infectious Diseases, Karolinska
Institutet, Stokholm, Sweden; 17Departement of
Infectious Diseases, Karolinska University Hospital,
Stockholm, Sweden; 18Department of Pneumology.
University General Hospital of Gran Canaria ‘‘Dr
Negrin’’, Las Palmas, Spain; 19ALOSA (Active
Learning over Sanitary Aspects) TB Academy, Spain;
20Paediatric Department, Vila Nova de Gaia Hospital
Centre, Vila Nova de Gaia Outpatient Tuberculosis
Centre, Vila Nova de Gaia, Portugal; 21Sydney
Infecious Diseases Institute (Sydney ID), The
University of Sydney, Sydney, NSW, Australia;
22Westmead Hospital, Sydney, NSW, Australia;
23Parramatta Chest Clinic, Parramatta, NSW,
Australia; 24School of Pharmacy, Faculty of Medicine
and Health, The University of Sydney, Sydney, NSW,
Australia; 25Department of Infectious Diseases,
Heartlands Hospital, University Hospitals
Birmingham NHS Foundation Trust, Birmingham,
UK; 26Centre for Lung Infection and Immunity Unit,
Department of Medicine, Division of Pulmonology
and UCT Lung Institute, University of Cape Town,
Cape Town, 27South African Medical Research
Council Centre for the Study of Antimicrobial
Resistance, University of Cape Town, Cape Town,
South Africa; 28Faculty of Infectious and Tropical
Diseases, London School of Hygiene & Tropical
Medicine, London, UK; 29Division of Infectious
Diseases, Department of Medicine, Vanderbilt
University Medical Center, Nashville, TN,
30Department of Global Health and Social Medicine,
Harvard Medical School, Boston, MA, USA;
31Tuberculosis Research Programme, SEPAR
(Sociedad Espa ˜ nola de Neumolog´ıa y Cirug´ıa
Tora´ cica), Barcelona, Spain; 32Desmond Tutu TB
Centre, Department of Paediatrics and Child Health,
Stellenbosch University, Tygerberg, South Africa;
33Department of Pediatrics, University of Wisconsin,
Madison, WI, USA; 34Division of Infectious Diseases
and International Health, University of Virginia,
Charlottesville, VA, USA; 35Department of
Epidemiology, School of Public Health and Key
Laboratory of Public Health Safety, Fudan University,
Shanghai, China; 36Tuberculosis Department Latin
American Society of Thoracic Diseases, Lima, Peru;
37Department of Infectious Diseases and
Microbiology, The Children’s Hospital at Westmead,
Westmead, NSW, Australia; 38Centre of Excellence in
Infectious Diseases Research, Antimicrobial
Pharmacodynamics and Therapeutics Group,
Department of Pharmacology and Therapeutics,
University of Liverpool, Liverpool, UK; 39Cl´ınica de
Tuberculosis, Instituto Nacional de Enfermedades
Respiratorias, M´exico City, Mexico; 40Division of
Paediatric Respirology, Department of Child Health,
Faculty of Medicine, Universitas Padjadjaran, Hasan
Sadikin Hospital, Bandung, Indonesia; 41Department
of Pulmonology of Central Hospital of Maputo,
Maputo, 42Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique;
43Infectious Disease Translational Research
Programme, Department of Medicine, Yong Loo Lin
School of Medicine, National University of
Singapore, Singapore, 44National University of
Singapore Institute for Health Innovation &
Technology (iHealthtech), Singapore, 45Division of
Infectious Diseases, Department of Medicine,
National University Hospital, Singapore; 46German
Central Committee Against Tuberculosis (DZK),
Berlin, Germany; 47Hospital Muniz and Instituto
Vaccarezza, Buenos Aires, Argentina; 48Infectious
Disease Pharmacokinetics Laboratory, College of
Pharmacy and Emerging Pathogens Institute,
University of Florida, Gainesville, FL, USA;
49Universidad Autonoma de Nuevo Leon, Facultad
de Medicina, Neumolog´ıa, CIPTIR, Monterrey,
Mexico; 50Faculdade de Medicina, Universidade
Federal do Rio Grande do Sul, Porto Alegre, RS,
Brazil; 51TB/HIV Research Centre, Faculty of
Medicine, Universitas Padjadjaran, Bandung,
Indonesia; 52Department of Biomedical Sciences,
Division of Pharmacology and Therapy, Faculty of
Medicine, Universitas Padjadjaran, Bandung,
Indonesia; 53Department of Internal Medicine,
Faculty of Medicine, Public Health, and Nursing,
Universitas Gadjah Mada, Yogyakarta, Indonesia;
54Centre for Tropical Medicine, Faculty of Medicine,
Public Health and Nursing, Universitas Gadjah
Mada, Yogyakarta, Indonesia; 55Division of
Respirology and Critical Care, Department of
Internal Medicine, Faculty of Medicine, Universitas
Padjadjaran/Hasan Sadikin General Hospital,
Bandung, Indonesia; 56 University of Texas Health
Science Center at Tyler, Tyler, TX, USA;
57Department of Pharmaceutical Biosciences,
Uppsala University, Uppsala, Sweden; 58Department
of TB & Respiratory Diseases, National Institute of
TB & Respiratory Diseases, New Delhi, India;
59Republican Research and Practical Centre for
Pulmonology and Tuberculosis, Minsk, Belarus;
60National Institute of Tuberculosis, Lung Diseases
and Thoracic Surgery, Faculty of Health, Catholic
University, Ruˇzomberok, Vyˇsn´e Ha´gy, Slovakia; 61
Department of Medicine, The University of Texas at
Tyler School ofMedicine, TX, USA; 62Department of
Pharmacy Practice, Texas Tech University Health
Science Center, Dallas, TX, USA; 63Department of
Clinical Pharmacology and Toxicology, St Vincent’s
Hospital, Sydney, NSW, Australia; 64Department of
Pharmacy, Uppsala University, Uppsala, Sweden;
65Infectious Diseases Unit, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Policlinico di
Sant’Orsola, Bologna, Italy; 66Department of
Medical and Surgical Sciences, Alma Mater
Studiorum University of Bologna, Bologna, Italy;
67Blizard Institute, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London, London, UK; 68Department of Infectious
Diseases, Austin Hospital, Melbourne, VIC,
Australia; 69P. D. Hinduja National Hospital and
Medical Research Centre, Mumbai, India;
70Department of Paediatrics, University Medical
Center Groningen, University of Groningen,
Groningen, the Netherlands; 72Department of
Pulmonary Diseases and Tuberculosis, Groningen,
and 73Tuberculosis Center Beatrixoord, University
Medical Center Groningen, University of Groningen,
Haren, the Netherlands; 74Victorian Tuberculosis
Program, Melbourne Health, VIC, Australia.
Correspondence to: Kasha P Singh, Department of
Infectious diseases, University of Melbourne, at the
Peter Doherty Institute for Infection and Immunity,
Melbourne, Australia. E-mail: kasha.singh@unimelb.
Compartilhar